Artificial Intelligence
April 23–25, 2018
Boston, MA • United States

2017 Cardiovascular Agenda

The 2017 World Medical Innovation Forum, focused on Cardiovascular, opened to more than 1,300 registrants from academia, industry, and government. Panelists, including 125 executives and key leaders, focused on the development and accessibility of new cardiovascular treatment innovations in a rapidly-evolving health care environment. Experts shared lessons they have learned, and how those insights are shaping the industry.  Fireside Chats, in-depth panel discussions, lively interactions, and the Disruptive Dozen—12 technologies that will reinvent cardiovascular care over the next decade—rounded out the Forum.

The 2018 panel topics focused on Artificial Intelligence will be announced soon. 

Monday, May 1, 2017

7:00 am - 8:00 am
Lilly Foyer
8:00 am - 11:30 am
Pfizer Ballroom
First Look: The Next Wave of Cardiology Breakthroughs

Harvard Medical School investigators describe their most promising work in rapid fire presentations highlighting commercial opportunities in cardiovascular and cardiometabolic care. Nineteen rising stars from BWH and MGH will present in 10-minute sessions.

For a full look at speakers and presentations, please visit the Highlight’s page.

11:45 am - 1:05 pm
3rd Floor and 7th Floor
Discovery Café Breakout Sessions: Sharing Perspectives

Seven intensive workshops led by our top faculty will address cutting-edge cardiovascular topics. Seating is reserved at the point of registration. Lunch included.

Topics to be covered include:

Cardiac Replacement Therapy: The Next Ten Years

Heart Failure: Back in The Game through New Pathways

Payment Models: Provider’s Perspective

Molecular Imaging: New Biological Endpoints – Function Over Structure

Open Innovation in Medical Devices: What is it? What Are the Barriers?

Wearables for Cardiovascular Health:  How to Validate and Integrate in Care Paths?

Image Based Artificial Intelligence: Which Cardiac Disease Segments and Why?

For a full list of speakers, please visit the Highlight’s page.

1:05 pm - 1:30 pm
1:30 pm - 1:35 pm
Boston Scientific Ballroom
1:35 pm - 1:55 pm
Boston Scientific Ballroom
Reinventing Cardiac Care

The Forum Co-Chairs will welcome attendees with a brief description of the key opportunities and challenges that will be highlighted in the Forum. They will emcee the entire afternoon program.

1:55 pm - 2:45 pm
Boston Scientific Ballroom
CEO Roundtable: Today's Learning, Tomorrow's Opportunities

Discussion on contribution of technology innovation to the treatment of cardiovascular disease reflecting on lessons and how they shape investment decisions.

2:45 pm - 3:35 pm
Boston Scientific Ballroom
Tackling the AFib Epidemic

Evolving trends in diagnosis, prevention, and treatment of atrial fibrillation. Factors that will influence patient care over the next 5 years are considered, including risk stratification, procedure and technology options, and potential implications of CMS policies, such as bundling.


3:35 pm - 4:05 pm
Boston Scientific Ballroom
4:05 pm - 4:55 pm
Boston Scientific Ballroom
Heart Failure's Therapeutic Mandate

One million patients are hospitalized annually for HF—80% of total US cost of HF management. After discharge from HF hospitalization, 24% are rehospitalized within 30 days, greater than 50% within 6 months. Perspective on disease management, addressing the issues of hospital readmission and optimizing therapies.


4:55 pm - 6:00 pm
Boston Scientific Ballroom

PAD is the most challenging atherosclerotic syndrome, largely due to the technological challenges of managing peripheral artery disease through minimally invasive strategies. Top physician, governmental, and industry leaders in the field discuss the potential for new breakthroughs including novel implantable devices, pharmacologic approaches, and reductions in associated cardiovascular morbidity and mortality.

The panel will also discuss, Below The Knee: The Persisting Unmet Need


6:00 pm - 6:45 pm
Lilly Foyer

Tuesday, May 2, 2017

7:00 am - 8:00 am
Lilly Foyer
7:00 am - 7:45 am
Pfizer Ballroom
FOCUS SESSION: Japan Today: Advancing Cardiometabolic Therapies

Discussion on unique aspects of cardiometabolic market in Japan, its projected trend over the next 5 years and explore transformative models of open innovation to accelerate development of new therapeutic options.

7:50 am - 8:00 am
Boston Scientific Ballroom
8:00 am - 8:50 am
Boston Scientific Ballroom
Pricing to Enable Affordability and Innovation

Balancing acceptable answers to high and escalating drug prices in the United States while making strides in medical innovation. Leaders in innovation, policy, care delivery, academia, and insurance discuss potential collaborative solutions.


8:50 am - 9:40 am
Boston Scientific Ballroom
CLINICAL HIGHLIGHT: Emerging Devices for Complex Structural Heart Disease

Evolution of mitral disease management, current practice and impact of new technologies on both repair and replacement, implications of a heterogeneous patient population, triage, timing of intervention.

9:40 am - 10:10 am
Boston Scientific Ballroom
10:10 am - 10:25 am
Lilly Foyer
10:25 am - 11:15 am
Boston Scientific Ballroom
Personal Monitoring for Disease Management

Considering the evolving trends in viability and utilization and the opportunities wearables may present for real-world clinical decision making.


11:15 am - 11:45 am
Boston Scientific Ballroom
12:00 pm
GE Ballroom
12:15 pm - 12:30 pm
GE Ballroom
Austen-Braunwald Award

Awarded to one BWH and one MGH First Look participant who embodies the innovative, entrepreneurial, and visionary spirit of cardiovascular legends W. Gerald Austen, MD and Eugene Braunwald, MD. Granted based on select criteria, including overall presentation quality, innovativeness, commercial potential, caliber of disruption, and market need.

1:00 pm - 1:10 pm
1:10 pm - 2:00 pm
Boston Scientific Ballroom
Global Clinical Trials: Next Generation Design and Scalability

Cardiovascular trials currently account for 10 percent of all clinical trial participants. Discussion on design and implementation of clinical studies globally, considering strategies for patient access, regulatory implications, cost containment and management of relationships with global service providers.

2:00 pm - 2:50 pm
Boston Scientific Ballroom
Precision Cardiovascular Medicine: What is Different This Time

Explore how precision medicine is changing the face of cardiovascular medicine specifically. The session will examine the impact of combined phenotypic and genotypic characterization on optimizing response to therapeutics, trial design, improving outcomes, and redefining reimbursement.

2:50 pm - 3:40 pm
Boston Scientific Ballroom
CV Investing in the Next Decade

View on investing landscape, opportunities in the CV/metabolic marketplace, the drugs, devices and diagnostics currently in pipelines and notable positive trends.

3:40 pm - 4:30 pm
Boston Scientific Ballroom
CLINICAL HIGHLIGHT: Optimizing Care for the 51%: New Market Opportunities

Address implications of gender as a key biological factor for personalized medicine. Stroke is likely to be the first cardiovascular event, tied to AF and secondarily to hypertension. Opportunities for medication utilization and optimization in context of, manifestation of disease and understanding the biology, complications, strategies to collect relevant clinical evidence, and treatment response.

4:30 pm - 5:20 pm
Boston Scientific Ballroom
Disruptive Therapeutic Platforms: New Tools, New Outcomes

Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases including heart failure. These emerging drugs could be considered in context of genomic/germ line screening, family history and epigenetics.

5:20 pm - 6:00 pm
Novartis Foyer

Wednesday, May 3, 2017

7:00 am - 7:30 am
Lilly Foyer
7:55 am - 8:45 am
Boston Scientific Ballroom
Innovation in Translational Trials

CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.


8:45 am - 9:15 am
Boston Scientific Ballroom
9:15 am - 10:05 am
Boston Scientific Ballroom
New Targets in Coronary Artery Disease

Cardiovascular trials have a proud history of providing some of the most robust data in evidence-based medicine. However the growing size and complexity of these trials imperils their future. This panel will discuss the design and implementation of clinical studies globally, considering strategies for patient access, leveraging electronic health records and mobile device data, personalized medicine, regulatory implications, cost containment and management of relationships with global service providers.

10:05 am - 10:25 am
Lilly Foyer
10:25 am - 10:55 am
Boston Scientific Ballroom
10:55 am - 11:45 am
Boston Scientific Ballroom
The Skinny on Fat: Therapeutic Opportunities

Explore the evolving role of adipose tissue as an active endocrine organ and discuss the possibilities to discover novel signaling pathways relevant to cardiovascular health and viable druggable targets.

11:45 am - 12:45 pm
Boston Scientific Ballroom
1:00 pm
Lilly Foyer

*Panels and speakers are subject to change.